Category Excessive IP

Evergreening is common

Dealing with intellectual property issues linked to affordability and access to medicines, included in the WHO Essential Medicines List (EML).

A liberal economists perspective on why patents may not promote innovation.

IP on basic research reduces subsequent scientific research and product development

Publicly generated patents should be licensed and managed in a way that makes products affordable

Patent protection leads to decreased quality of diagnostics (in gene research)

Patent protection does not contribute to innovation (in gene research)

Only small proportion of patent portfolio applied for before product launch, patents continue steadily after launch

Pharma takes out as many patents as they can

Only 2% of patent apps refused by EPO 2000-7

Review of secondary patents (prodrugs, polymorphs, salts)

US Supreme Court: Can’t patent genes (Myriad case)

Dutch customs officials delay generics shipment for months due to EU laws on counterfeits (2009)

USTR Special 301 report (still) criticising use of TRIPS flexibilities

Nature editorial blasts university relationships with patent trolls

TPP seeks to allow patenting of medical *methods*